Key Financials Snapshot

TTM · Consolidated · ₹ in Cr
Market Cap
₹23 Cr.
Stock P/E
-9.5
P/B
3
Current Price
₹118
Book Value
₹ 38.7
Face Value
10
52W High
₹218.2
52W Low
₹ 113.9
Dividend Yield
0%

Skybiotech Healthcar Overview

Business

Skybiotech Healthcare Ltd. is indicated to operate within the Textile sector in India. Given its industry classification, its core business model would likely involve manufacturing, processing, and/or trading of various textile products. This could range from raw materials like yarn, to woven or knitted fabrics, home textiles, technical textiles, or finished apparel. The company would generate revenue by selling these textile products to domestic consumers, other manufacturers, retailers, or through exports to international markets. The "Healthcare" in its name might suggest a specialization within technical textiles, focusing on medical textiles (e.g., surgical gowns, bandages, implants, hygiene products) or a future diversification strategy.

Revenue Mix

Specific segment breakdown and revenue mix for Skybiotech Healthcare Ltd. are not available from the provided information. In a typical textile company, segments might include:

Yarn Manufacturing (e.g., cotton, synthetic, blended yarns)

Fabric Manufacturing (weaving, knitting, dyeing, printing)

Apparel & Garments

Home Textiles (bed linen, towels, curtains)

Technical Textiles (e.g., medical, automotive, industrial applications)

Given the company name, a significant portion of revenue could potentially come from technical textiles for healthcare applications if it operates in that niche within the textile sector.

Industry

The Indian textile industry is one of the oldest and largest industries in the country, contributing significantly to industrial output, employment, and exports. It is highly fragmented, comprising a mix of large integrated mills, small and medium-sized enterprises (SMEs), and unorganized players. Competition is intense, both domestically and internationally. Without specific operational details, Skybiotech Healthcare Ltd.'s positioning is unclear. It could be a broad-based textile manufacturer, a niche player specializing in specific textile products (e.g., technical textiles for medical use, aligning with its name), or focused on a particular value chain segment (e.g., yarn spinning vs. garmenting). Its ability to compete would depend on factors like cost efficiency, product quality, innovation, and market access.

MOAT

Without specific information, it is difficult to ascertain if Skybiotech Healthcare Ltd. possesses a durable competitive advantage. Potential moats in the textile industry include:

Cost Leadership: Achieved through economies of scale, vertical integration, and efficient operations.

Niche Specialization: Expertise in producing high-value or technical textiles (e.g., medical textiles, which could be relevant given the name), creating barriers to entry.

Strong Brand: For consumer-facing products, though less common for B2B textile manufacturers.

Customer Relationships & Supply Chain: Deep relationships with buyers or efficient supply chain management.

Proprietary Technology/Processes: Unique manufacturing processes or product innovations.

If the company indeed operates in technical textiles for healthcare, its moat could stem from specialized manufacturing capabilities, regulatory approvals, and R&D in biomaterials or functional textiles.

Growth Drivers

Key factors that could drive growth for Skybiotech Healthcare Ltd. over the next 3-5 years include:

Increasing Domestic Consumption: Rising disposable incomes and changing lifestyles in India drive demand for textiles and apparel.

Export Opportunities: Government initiatives (e.g., PLI schemes, trade agreements), global demand for quality textiles, and competitive pricing can boost exports.

Growth in Technical Textiles: Rapidly growing segment driven by demand from various industries including healthcare, automotive, and construction. This aligns with the company's name.

Product Innovation & Diversification: Introduction of new materials, designs, and value-added products.

Capacity Expansion: Investing in modernization and increasing manufacturing capacity to meet demand.

Risks

Key business risks for Skybiotech Healthcare Ltd. within the textile sector include:

Raw Material Price Volatility: Fluctuations in prices of cotton, synthetic fibers, and dyes can impact profitability.

Intense Competition: Highly fragmented industry with significant domestic and international competition leading to pricing pressures.

Global Economic Slowdown: Affects export demand and consumer spending, particularly for discretionary textile products.

Fashion & Trend Changes: Rapid shifts in consumer preferences can lead to inventory obsolescence for apparel/fashion-oriented textiles.

Regulatory & Environmental Compliance: Evolving labor laws, environmental regulations (e.g., wastewater treatment), and trade policies can increase operational costs.

Currency Fluctuations: For companies involved in significant exports or imports, exchange rate volatility can impact margins.

Management & Ownership

Information regarding the promoters, specific management quality, and detailed ownership structure for Skybiotech Healthcare Ltd. is not available from the provided data. Typically, many Indian companies, particularly in traditional sectors like textiles, are promoter-driven with significant family ownership and involvement in management.

Outlook

Skybiotech Healthcare Ltd., operating in the Indian textile sector, presents a balanced outlook. The bull case is supported by the robust growth potential of the Indian textile industry, particularly in niche segments like technical textiles (which aligns with the "Healthcare" in its name, suggesting a potential strategic focus on medical textiles). Leveraging India's competitive manufacturing costs, growing domestic market, and increasing export opportunities could drive expansion. Operational efficiencies, product innovation, and strong market linkages could enable the company to capture market share.

The bear case highlights significant challenges such as intense competition, volatility in raw material prices, and susceptibility to global economic cycles impacting export demand. Without a clear competitive moat or significant scale, the company could face margin pressures. Furthermore, if the "Healthcare" in its name implies a future pivot or diversification that is not yet realized or clearly defined, there could be execution risks and brand confusion within its current textile operations. The fragmented nature of the industry requires continuous innovation and cost management to sustain profitability and growth.

Skybiotech Healthcar Share Price

Live · BSE · Inception: 1983
₹ | |
Volume
Price

Key Financials — Profit & Loss

₹ in Cr · Consolidated · annual

Skybiotech Healthcar Quarterly Results

#(Fig in Cr.) Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Net Sales 0 0 2 3 1 2 2 1 2 0
Other Income 1 0 0 0 -0 0 0 0 0 0
Total Income 1 0 2 3 1 2 2 1 2 1
Total Expenditure 0 0 2 3 2 2 2 1 3 1
Operating Profit 1 0 0 -0 -1 0 -0 -0 -1 -0
Interest 0 0 0 0 -0 0 0 0 0 0
Depreciation -0 0 0 0 0 0 0 0 0 0
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 1 0 -0 -0 -1 -0 -0 -0 -1 -1
Provision for Tax 0 0 0 -0 -0 0 0 0 -1 0
Profit After Tax 0 0 -0 -0 -1 -0 -0 -0 -0 -1
Adjustments 0 0 0 -0 0 -0 -0 0 0 0
Profit After Adjustments 0 0 -0 -0 -1 -0 -0 -0 -0 -1
Adjusted Earnings Per Share 2.5 1.3 -1.3 -2.1 -5.7 -0.1 -1.6 -2.5 -1.6 -3

Skybiotech Healthcar Profit & Loss

#(Fig in Cr.) Mar 2025 TTM
Net Sales 7 5
Other Income 0 0
Total Income 7 6
Total Expenditure 9 7
Operating Profit -2 -1
Interest 0 0
Depreciation 1 0
Exceptional Income / Expenses 0 0
Profit Before Tax -2 -2
Provision for Tax -0 -1
Profit After Tax -2 -1
Adjustments 0 0
Profit After Adjustments -2 -1
Adjusted Earnings Per Share -12.4 -8.7

Skybiotech Healthcar Balance Sheet

#(Fig in Cr.) Mar 2025
Shareholder's Funds 9
Minority's Interest 2
Borrowings 7
Other Non-Current Liabilities -1
Total Current Liabilities 3
Total Liabilities 19
Fixed Assets 12
Other Non-Current Assets 5
Total Current Assets 2
Total Assets 19

Skybiotech Healthcar Cash Flow

#(Fig in Cr.) Mar 2025
Opening Cash & Cash Equivalents 9
Cash Flow from Operating Activities -1
Cash Flow from Investing Activities -10
Cash Flow from Financing Activities 1
Net Cash Inflow / Outflow -9
Closing Cash & Cash Equivalent -0

Skybiotech Healthcar Ratios

# Mar 2025
Earnings Per Share (Rs) -12.37
CEPS(Rs) -9.54
DPS(Rs) 0
Book NAV/Share(Rs) 46.93
Core EBITDA Margin(%) -31.97
EBIT Margin(%) -34.23
Pre Tax Margin(%) -34.4
PAT Margin (%) -33.59
Cash Profit Margin (%) -25.91
ROA(%) -12.35
ROE(%) -26.36
ROCE(%) -14.91
Receivable days 21.98
Inventory Days 82.48
Payable days 62.86
PER(x) 0
Price/Book(x) 3.49
Dividend Yield(%) 0
EV/Net Sales(x) 5.5
EV/Core EBITDA(x) -20.73
Net Sales Growth(%) 0
EBIT Growth(%) 0
PAT Growth(%) 0
EPS Growth(%) 0
Debt/Equity(x) 0.8
Current Ratio(x) 0.75
Quick Ratio(x) 0.13
Interest Cover(x) -201.13
Total Debt/Mcap(x) 0.23

Growth Rates

Compounded annual
# 1 Year 3 Year 5 Year 10 Year
Sales CAGR — — — —
Operating Profit CAGR — — — —
PAT CAGR — — — —
Share Price CAGR -41% +7% +31% -2%
ROE Average -26% -26% -26% -26%
ROCE Average -15% -15% -15% -15%

Skybiotech Healthcar Shareholding Pattern

Latest · Jun 2026
100% held
Promoters 63.48 %
FII 0 %
DII (MF + Insurance) 0 %
Public (retail) 36.52 %
# Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Promoter 62.7162.7162.7162.7163.4863.4863.4863.4863.4863.48
FII 0000000000
DII 0000000000
Public 37.2937.2937.2937.2936.5236.5236.5236.5236.5236.52
Others 0000000000
Total 100100100100100100100100100100

Skybiotech Healthcar Peer Comparison

Skybiotech Healthcar Quarterly Price

10-year quarterly close · BSE
Show Value Show %

News & Updates

See more…

Skybiotech Healthcar Pros & Cons

Pros

  • Debtor days have improved from 62.86 to days.
  • Company has reduced debt.

Cons

  • Company has a low return on equity of -26% over the last 3 years.
Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

whatsapp